Posted on 09/02/2010 in Pharmacy Supplier News Allergan, a provider of pharmacy products, has announced that the Food and Drug Administration (FDA) has approved its hyaluronic acid filler JUVEDERM XC.
A variation of the previously approved JUVEDERM, the product utilises the latest advancement in hyaluronic acid (HA) dermal fillers and contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds.
JUVEDERM XC's formulation features 0.3 per cent of the preservative-free lidocaine, which numbs the treatment area within seconds and provides the results as demonstrated with the existing formulation.
Robert Grant, Allergan's corporate vice-president, said: "We lead innovation in the dermal filler category with the first and only smooth-consistency gel hyaluronic acid dermal filler approved by the FDA to last up to a year."
In other Allergan news, last October the organisation announced that it was contesting a ruling that forbids it from sharing relevant information to assist physicians in evaluating the risks and benefits of Botox (onabotulinumtoxinA). Other news stories from 09/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
